Takeda Pharmaceutical plans to dispose of 71,700 shares of common stock at 4,119 JPY per share on July 17, 2026. This is part of an incentive system granted to directors, with a transfer restriction period of more than 3 years. The total disposal amount is approximately 295 million JPY.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4401","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-06-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4401-20260619-01.pdf","jir_short_summary":"Takeda Pharmaceutical plans to dispose of 71,700 shares of common stock at 4,119 JPY per share on July 17, 2026. This is part of an incentive system granted to directors, with a transfer restriction period of more than 3 years. The total disposal amount is approximately 295 million JPY.","jir_summary":"### Overview of the Disposal\nTakeda Pharmaceutical plans to dispose of 71,700 shares of common stock at 4,119 JPY per share on July 17, 2026, totaling approximately 209.53 million JPY. This is conducted as part of an incentive system for directors, with a transfer restriction period set at over 3 years. The disposal is carried out as part of a stock compensation scheme through the contribution of monetary compensation claims as physical assets, with further details and objectives of the system also described.\n\n### Background of the System and Future Outlook\nThis system aims to enhance corporate value and share value sharing with shareholders, with 24 eligible participants. The disposal is conducted at a fair price based on the market stock price and will be released after the transfer restriction period expires. The company is expected to continue strengthening director incentives and achieving sustainable improvements in corporate value.","jir_financial_highlights":"Number of shares disposed: 71,700 shares (Unknown)\nDisposal value: 4,119 JPY (Unknown)\nTotal disposal amount: 295,332,300 JPY (Unknown)","jir_category":"","jir_hashtags":"#TakedaPharmaceutical, #IRRelated, #JapaneseStocks","jir_key_figures":"Number of shares disposed: 71,700 shares\nDisposal value: 4,119 JPY\nTotal disposal amount: 295,332,300 JPY","jir_meta_title":"\u3010Takeda Pharmaceutical\u3011Share Buyback and Director Incentives | June 2026","jir_meta_description":"Takeda Pharmaceutical plans to dispose of 71,700 shares at 4,119 JPY in July 2026. This is part of an incentive system for directors, with a transfer restriction period of over 3 years. Details explained.","jir_og_title":"\u3010Takeda Pharmaceutical\u3011Share Buyback and Director Incentives | June 2026","jir_og_description":"Takeda Pharmaceutical is disposing of shares as part of an incentive system for directors. Please check the details.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7996,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_cancellation","footnotes":""},"sector":[],"importance":[],"class_list":["post-66127","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n